Amro M. Abdelrahman

The paper identifies LCK-driven EGFR activation as a therapeutic target in cholangiocarcinoma, showing EGFR activity predicts response to EGFR inhibition.

This study identifies AKT as a regulator of YAP stability and shows that AKT inhibition triggers ESCRT-dependent YAP degradation, enhancing the efficacy of RAS inhibition in pancreatobiliary cancers.

This study identifies KLF5-bound enhancers in pancreatic cancer that regulate cell survival, showing their subtype-independent role in maintaining tumor viability.

This study identifies TNF and TWEAK as activators of canonical and noncanonical NF-κB signaling in PDAC, revealing distinct epigenetic dependencies of RELA and RELB.

This study identifies biomarkers and resistance mechanisms to SFK-YAP inhibition in cholangiocarcinoma using multiomic profiling and shows synergy with chemotherapy.